Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3911 ARTÍCULOS , VIENDO DEL 1126 AL 1140

Levodopa-Responsive Parkinsonism with Prominent Freezing and Abnormal Dopamine Transporter Scan Associated with SANDO Syndrome

Batla A, Erro R, Ganos C, Stamelou M, Bhatia KP.

Mov Disord Clin Pract. 2015 Jun 2;2(3):304-307. doi: 10.1002/mdc3.12164. eCollection 2015 Sep.

Intranasal delivery of dopamine to the striatum using glycol chitosan/sulfobutylether-β-cyclodextrin based nanoparticles

Di Gioia S, Trapani A, Mandracchia D, De Giglio E, Cometa S, Mangini V, Arnesano F, Belgiovine G, Castellani S, Pace L, Lavecchia MA, Trapani G, Conese M, Puglisi G, Cassano T.

Eur J Pharm Biopharm. 2015 Aug;94:180-93. doi: 10.1016/j.ejpb.2015.05.019. Epub 2015 May 30.

Discriminating features of gait performance in progressive supranuclear palsy

Amano S, Skinner JW, Lee HK, Stegemöller EL, Hack N, Akbar U, Vaillancourt D, McFarland NR, Hass CJ.

Parkinsonism Relat Disord. 2015 Aug;21(8):888-93. doi: 10.1016/j.parkreldis.2015.05.017. Epub 2015 May 29.

Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease

Takahashi K, Foster JB, Lin CL.

Cell Mol Life Sci. 2015 Sep;72(18):3489-506. doi: 10.1007/s00018-015-1937-8. Epub 2015 Jun 2.

Unmasking nonmotor symptoms of Parkinson disease

LaRocco SA.

Nursing. 2015 Jul;45(7):26-32; quiz 32-3. doi: 10.1097/01.NURSE.0000466443.27431.b3.

Intranasal drug delivery in neuropsychiatry: focus on intranasal ketamine for refractory depression

Andrade C.

J Clin Psychiatry. 2015 May;76(5):e628-31. doi: 10.4088/JCP.15f10026.

Hyperhomocysteinemia: Impact on Neurodegenerative Diseases

Sharma M, Tiwari M, Tiwari RK.

Basic Clin Pharmacol Toxicol. 2015 Nov;117(5):287-96. doi: 10.1111/bcpt.12424. Epub 2015 Jun 19.

NALP3 inflammasome activation in protein misfolding diseases

Shi F, Kouadir M, Yang Y.

Life Sci. 2015 Aug 15;135:9-14. doi: 10.1016/j.lfs.2015.05.011. Epub 2015 May 31.

Antidepressive treatments for Parkinson's disease: A systematic review and meta-analysis

Bomasang-Layno E, Fadlon I, Murray AN, Himelhoch S.

Parkinsonism Relat Disord. 2015 Aug;21(8):833-42; discussion 833. doi: 10.1016/j.parkreldis.2015.04.018. Epub 2015 May 16.

Apomorphine hydrochloride for the treatment of Parkinson's disease

Unti E, Ceravolo R, Bonuccelli U.

Expert Rev Neurother. 2015;15(7):723-32. doi: 10.1586/14737175.2015.1051468. Epub 2015 Jun 2.

Amyloids or prions? That is the question

Sabate R, Rousseau F, Schymkowitz J, Batlle C, Ventura S.

Prion. 2015;9(3):200-6. doi: 10.1080/19336896.2015.1053685.

Memory dysfunction

Matthews BR.

Continuum (Minneap Minn). 2015 Jun;21(3 Behavioral Neurology and Neuropsychiatry):613-26. doi: 10.1212/01.CON.0000466656.59413.29.

Perceptual-motor dysfunction

Finney GR.

Continuum (Minneap Minn). 2015 Jun;21(3 Behavioral Neurology and Neuropsychiatry):678-89. doi: 10.1212/01.CON.0000466660.82284.69.

Depression

Schulz PE, Arora G.

Continuum (Minneap Minn). 2015 Jun;21(3 Behavioral Neurology and Neuropsychiatry):756-71. doi: 10.1212/01.CON.0000466664.35650.b4.

Clozapine Treatment for Impulse Control Disorders in Parkinson's Disease Patients: A Case Series

Liang J, Groves M, Shanker VL.

Mov Disord Clin Pract. 2015 Jun 4;2(3):283-285. doi: 10.1002/mdc3.12167. eCollection 2015 Sep.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias